International Hyperpolarized C-13 MRI Seminar
Date
View Flyer: https://ucsf.box.com/v/hmtrc-22-feb-seminar
Join us with this Zoom 1-click Link: https://us02web.zoom.us/j/85169799890
Sign up for Seminar Series Updates: https://mailchi.mp/ucsf.edu/inthp-c13-mri-seminar
3236 America/Los_Angeles publicType
Time Duration
View Flyer: https://ucsf.box.com/v/hmtrc-22-feb-seminar
Join us with this Zoom 1-click Link: https://us02web.zoom.us/j/85169799890
Sign up for Seminar Series Updates: https://mailchi.mp/ucsf.edu/inthp-c13-mri-seminar
Speakers
HP Radiologist Leadership Committee
Michael Ohliger, MD, PhD, is an Associate Professor in Residence in the Department of Radiology and Biomedical Imaging at the University of California, San Francisco. Dr. Ohliger obtained his PhD in Medical Physics from the Massachusetts Institute of Technology Harvard/MIT Division of Health Sciences and Technology in 2005, and he received his MD in Medicine from Harvard Medical School in 2007. He completed his residency in Diagnostic Radiology and fellowship training in Abdominal Imaging at UCSF. He joined the UCSF faculty in 2013.
Dr. Ohliger’s main research involves the development and clinical translation of new MRI techniques for the abdomen and pelvis, with a focus on molecular imaging of liver tumors, liver metabolism and liver injury. Current research projects involve using hyperpolarized carbon-13 MRI to image liver tumors as well as fatty liver disease. Dr. Ohliger also has a major research effort (together with Dr. David Wilson and Oren Rosenberg) developing novel methods for imaging bacterial injection.
TR&D1 Leader
HMTRC Executive Committee Member
Presentation 1: HP 13C MR Acquisition Developments Update
Senior Scientist at the Sunnybrook Research Institute
Presentation 2: Hyperpolarized 13C MRI of the Human Brain
Our lab is focused on making measurements and images using 13C-labelled metabolites, and studying how these change in disease. We also develop the required imaging methodology and hardware to perform this new form of MRI. To give metabolites a magnetic signal large enough to enable MRI, dynamic nuclear polarization (DNP) is applied in order to magnetize concentrated samples of a substrate, such as 13C-labeled pyruvate, and the resulting solution is injected in vivo. We are interested in the metabolic characterization of damaged heart muscle in order to detect the early stages of heart failure and select therapies, as well as metabolic characterization of cancer as a possible method for staging and for measuring response to therapy.
Our group specializes in the development of new methodology and hardware for imaging 13C-labelled compounds in humans, and have used these to make the first metabolic images of the human heart.